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ABSTRACT
In our prior publications we characterized a conserved acetylation motif (K(R)
xxKK) of evolutionarily related nuclear receptors. Recent reports showed that 
peroxisome proliferator activated receptor gamma (PPARγ) deacetylation by SIRT1 
is involved in delaying cellular senescence and maintaining the brown remodeling 
of white adipose tissue. However, it still remains unknown whether lysyl residues 
154 and 155 (K154/155) of the conserved acetylation motif (RIHKK) in Pparγ1 are 
acetylated. Herein, we demonstrate that Pparγ1 is acetylated and regulated by both 
endogenous TSA-sensitive and NAD-dependent deacetylases. Acetylation of lysine 
154 was identified by mass spectrometry (MS) while deacetylation of lysine 155 
by SIRT1 was confirmed by in vitro deacetylation assay. An in vivo labeling assay 
revealed K154/K155 as bona fide acetylation sites. The conserved acetylation sites 
of Pparγ1 and the catalytic domain of SIRT1 are both required for the interaction 
between Pparγ1 and SIRT1. Sirt1 and Pparγ1 converge to govern lipid metabolism 
in vivo. Acetylation-defective mutants of Pparγ1 were associated with reduced lipid 
synthesis in ErbB2 overexpressing breast cancer cells. Together, these results suggest 
that the conserved lysyl residues K154/K155 of Pparγ1 are acetylated and play an 
important role in lipid synthesis in ErbB2-positive breast cancer cells. 
INTRODUCTION
Peroxisome proliferator-activated receptor gamma 
(PPARγ) is a member of the nuclear receptor (NR) 
superfamily, which functions as a ligand-dependent 
transcription regulator. Due to alternative splicing and 
differential promoter utilization, PPARγ exists in two 
isoforms, PPARγ1 and PPARγ2. The murine Pparγ2 
encodes an additional 30 amino acids (28 amino acids in 
human PPARγ) at its N-terminus. PPARγ1 is expressed 
in many tissues at low levels, while PPARγ2 is expressed 
at high levels and is restricted to adipose tissue. Mouse 
PPARγ1 and human PPARγ1 shared 98% homology in 
protein sequence. PPAR regulates diverse biological 
functions including adipocyte differentiation [1], 
lipogenesis [2], inflammation [3], insulin sensitivity [4], 
cellular proliferation [5], and autophagy [6]. Both natural 
ligands including prostaglandins (15d-PGJ2) and synthetic 
ligands including the anti-diabetic thiazolidinediones 
(TZD) are known to induce PPARγ activity. 
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PPARγ activity is also regulated by post-
translational modifications, including phosphorylation, 
sumoylation, ubiquitination and acetylation. Among 
these post-translational modifications, phosphorylation 
has been extensively studied. The Activation Function 1 
(AF1) region of PPARγ is phosphorylated by mitogen-
activated protein kinases (MAPKs) (PPARγ1 at Ser82 
and PPARγ2 at Ser112), which represses transcriptional 
activity by inhibiting ligand binding and altering cofactor 
recruitment [7-9]. Phosphorylation of the same residue 
by cyclin-dependent kinases, Cdk7 and Cdk9, promotes 
PPARγ  activity [10, 11]. Recently it was reported 
that PPARγ2 is phosphorylated at Ser273 by cyclin-
dependent kinase 5 (CDK5) [12]. Phosphorylation of 
PPARγ2 by CDK5 inversely correlates with TZD-induced 
insulin sensitivity in human. These studies indicate that 
phosphorylation of PPARγ  at different sites or even at 
the same sites results in different transcriptional and 
functional outcomes depending on the physiological 
context and the kinases involved. This phenomenon is well 
known among other post-translationally modified nuclear 
receptors. Several different acetylation sites (K266, 268, 
302, and 303) of estrogen receptor alpha (ERα) have 
been reported [13, 14]. Acetylation of ERα at lysine 266 
and 268 enhances the DNA binding and transactivation 
activities of the receptor, however acetylation of lysine 
302 and 303 suppresses the transactivation function. 
Recent publications showed that PPARγ is acetylated 
by p300 or CBP and deacetylated by silent mating type 
information regulation 2 homolog 1 (SIRT1). PPARγ 
acetylation participated in cellular senescence [15] and 
the brown remodeling of white adipose tissue (Lysine 
268 and 293) [16]. Even though acetylation has been well 
characterized in the androgen receptor (AR) and ERα at 
a conserved lysine motif (K(R)xxKK) which is shared 
amongst evolutionarily related nuclear receptors [14, 17-
19], the function of this conserved lysine motif in Pparγ 
was not known. 
Increased de novo fatty acid synthesis, which 
contributes to energy homeostasis and tumor growth, 
is a common feature of human tumors. The survival of 
breast cancer cells, especially those with ErbB2/Her2 
overexpression, is highly dependent upon the lipid 
metabolism induced by Pparγ, which protects cells from 
palmitate toxicity [20]. Our previously published work 
showed that a constitutively active Pparγ1 mutant (PγCA) 
collaborated with oncogenic ErbB2 to promote mammary 
tumor growth [21].
Herein, we characterized Pparγ1 acetylation at the 
conserved lysine motif (RIHKK). Our studies revealed 
that Pparγ1 is acetylated at nine distinct lysyl residues. 
The acetylation of Pparγ1 lysine 154 was confirmed by a 
chemically modified trypsin mapping protocol developed 
for histone acetylation mapping. The K155 residue, 
which is located in close proximity to the DNA binding 
domain, was deacetylated by SIRT1. The Pparγ1 mutant 
K154/155R reduced the acetylation levels assessed 
by in vivo labeling. The acetylation-defective mutant 
K154/155A or K154/155Q showed reduced interaction 
with SIRT1. The Pparγ1 K154/155 determines the 
induction of lipogenesis in ErbB2 overexpressing breast 
cancer cells. Loss of SIRT1 function and gain of Pparγ1 
function converge on common gene signaling pathways. In 
summary, these results suggest that the acetylation of the 
conserved lysine motif (K154/155) of Pparγ1 determines 
lipid synthesis in ErbB2-positive breast cancer cells. 
RESULTS
Acetylation of lysyl residues of conserved motif in 
Pparγ
Pparγ acetylation has historically been investigated 
by using anti-acetyl lysine antibodies [15, 16]. In order 
to determine Pparγ acetylation, we firstly performed in 
vivo labeling assays. The incorporation of [3H] acetyl-
CoA into Pparγ was only seen in cells transfected with 
3xFLAG-tagged Pparγ1, but not control vector (Fig. 1A). 
The addition of trichostatin A (TSA), an inhibitor of type I/
II HDACs, or nicotinamide (NA), an inhibitor of Sirtuins, 
increased [3H]-labeled Pparγ (Fig. 1A). These results 
suggest that the basal acetylation levels of Pparγ are very 
low, and endogenous class I/II and III HDACs are both 
involved in the deacetylation of Pparγ.
The residues in proximity to Pparγ1 K154/155 
resemble the acetylated motif of ERα and AR [14, 17] 
and are conserved among different species (Fig. 1B). In 
order to determine whether the lysyl residues K154 and 
K155 in the conserved motif of Pparγ are acetylated, 
we conducted mass spectrometry (MS) of immune-
precipitated 3xFLAG-tagged Pparγ1 from HEK 293 cells. 
These lysyl residues contain numerous basic amino acids 
which are often resistant to conventional trypsin mapping. 
This was confirmed by trypsin and chymotrypsin mapping 
(Fig. S1A), which demonstrated that mapping covered 
92% of the protein, but omitted the conserved acetylation 
motif. Therefore, trypsin mapping was conducted using a 
chemical-derivatization protocol [22]. While the sequence 
coverage (Fig. S1B) is not as high as conventional trypsin 
or chymotrypsin mapping, the spectral counts and Mascot 
scores for acetylated peptides were higher, and multiple 
peptides with overlapping sequences mapped to the same 
site (Fig. S2A, B). A total of nine lysyl residues including 
K154 were identified as targets for acetylation in vivo 
(Fig. 1C and Fig. S2A). Using 3-dimensional structural 
mapping, lysyl residues 156 and 157 of human PPARγ1 
(lysyl residues 154 and 155 in mouse Pparγ) are located 
in the DNA binding domain in close juxtaposition to the 
ligand binding domain (Fig. 1D). The side chain nitrogen 
of the K156 (K154 in mouse, bottom yellow residue) 
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is approximately 8A˚ from the phosphate backbone of 
DNA, too far for a hydrogen bond, and therefore does 
not directly contact DNA (orange in image) but rather 
appears solvent accessible. This data is consistent with 
its observed acetylation by MS. The adjacent K157 
(K155 in mouse, top yellow residue) side chain nitrogen 
is approximately 13A˚ from the DNA backbone, forms 
a hydrogen bond with E378 of human PPARγ but 
appears solvent inaccessible. To verify the acetylation of 
the conserved lysine motif in Pparγ, an in vivo labeling 
assay was performed in HEK 293 cells transfected with 
3xFLAG-tagged Pparγ1 wild-type or K154/155R mutant. 
Wild-type Pparγ1 was acetylated while the K154/155R 
mutation significantly reduced the incorporation of [3H] 
acetyl-CoA (Fig. 1E), suggesting that K154/155 are bona 
fide acetylation sites.
As NA increased the Pparγ acetylation, we 
investigated whether Pparγ1 K154/155 could serve as a 
substrate for SIRT1. A synthetic peptide containing the 
sites was used as a substrate for an in vitro deacetylation 
assay. The kinetic parameters for deacetylation of this 
peptide were similar to that of a p53 peptide known to 
be deacetylated by SIRT1 (Fig. 1F). Confirmation of the 
peptide deacetylation (K155) was obtained by MS (Fig. 
1G, H). Thus, consistent with our original findings [13, 
17] in which the lysyl residues of a conserved motif (K(R)
xxKK) in ERα and AR are acetylated, and subsequent 
studies of other nuclear receptors (NRs) [18, 19, 23-25], 
Figure 1: Acetylation of lysyl residues within conserved acetylation motif of Pparγ. (A) The inhibition of either TSA-sensitive 
or NAD-dependent deacetylase activity induced Pparγ acetylation assayed by in vivo [3H]-sodium acetate labeling. (B) The conserved 
acetylation motif in Pparγ is shown for several species. (C) Tandem MS (MS/MS) spectrum of Pparγ showing the acetylation at K154 (Red 
letter), “Ac” indicates lysine (K) residues that is acetylated. (D) A cylinder model for the crystal structure of hPPARγ1 with DNA double 
helix (orange color). The lysine 156 and 157 are shown in yellow. (E) Mutant K154/155R significantly reduced Pparγ acetylation. (F) The 
deacetylation rate of Pparγ or p53 peptide of different concentrations by SIRT1. The lines are best fits to the Michaelis-Menten equation and 
determine the following values for Km and Vmax: PPARγ (•), Km is 60.1 µM, vmax is 0.016s-1; ASp53 (ƀ), Km is 90.5 µM, vmax is 0.013s-1. 
(G) HPLC chromatograms of Pparγ peptide deacetylation with SIRT1 enzyme. Untreated diacetylated Pparγ peptide is shown at bottom 
chromatogram. (H) MS/MS spectrum of the deacetylated Pparγ. Asterisk indicated deacetylated lysine residue. 
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Pparγ1 is also acetylated at the conserved lysine motif. Mutation of Pparγ1 at K154/155 reduces SIRT1 
binding
The association between Pparγ1 and SIRT1 was 
next examined by immune-precipitation and Western 
Figure 2: Mutation of Pparγ at K154/155 reduces SIRT1 binding. (A) Schematic diagram of Myc-tagged SIRT1 wild-type. 
(B) Schematic diagrams of 3xFLAG-tagged Pparγ1 full length and internal deletion mutants. (C) HEK 293T cells were transfected with 
the indicated plasmids. Immuno-precipitations with anti-FLAG antibody were conducted, and Western blot was performed by indicated 
antibodies. The abundance of SIRT1, PPARγ internal deletions in input are shown. (D) Schematic diagrams of 3xFLAG-tagged Pparγ1 
full length and individual domains. (E) HEK 293T cells were transfected with the indicated plasmids. Immuno-precipitations with anti-
FLAG antibody were conducted, and Western blot was performed by indicated antibody. The bands for 3x FLAG-tagged Pparγ full 
length and individual domains are indicated by an asterisk. (F) Schematic diagrams of 3xFLAG-tagged Pparγ1, Myc-tagged SIRT1 wild-
type and catalytic point mutation. (G) HEK 293T cells were transfected with the indicated plasmids. Immuno-precipitations with anti-
FLAG antibody were conducted, and Western blot was performed by indicated antibody. All experiments were performed at least 3 times, 
representative figures are shown.
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blot analyses. We firstly examined the domains of Pparγ1 
required for SIRT1 binding. Expression vectors encoding 
Myc-tagged SIRT1 (Fig. 2A) together with FLAG-
tagged Pparγ1 or internal deletion mutants (Fig. 2B) were 
transiently introduced into HEK 293T cells. Immune-
precipitation was performed. Protein expression was 
evidenced by Western blot of the input protein using an 
anti-FLAG antibody for Pparγ1 and mutants, and an anti-
Myc antibody for SIRT1 (Fig. 2C). SIRT1 was detected 
in immune-precipitated wild-type Pparγ1. Deletion of the 
AF-1 domain or ligand binding domain (LBD) of Pparγ1 
enhanced relative SIRT1 binding. Deletion of the DNA 
binding domain (DBD) and/or hinge region reduced 
binding (Fig. 2C). Given that deletion of the DBD and/
or hinge region reduced SIRT1 binding, we determined 
whether SIRT1 is associated with the individual DBD or 
hinge domains. Expression vectors encoding individual 
Pparγ1 domains (Fig. 2D) were co-expressed with SIRT1 
expression vector in HEK 293T cells. Western blot with 
anti-Myc antibody showed either the DBD or hinge region 
of Pparγ1 was sufficient for association with SIRT1. The 
relative binding of SIRT1 to the AF1 region and LBD 
was reduced compared to wild-type Pparγ1 (Fig. 2E). 
We further studied the interaction between the Pparγ1 
K154/155 mutation and SIRT1. As shown in Figure 2F 
and 2G, both K154/155A and K154/155Q demonstrate 
reduced binding to SIRT1. These results suggest that the 
DBD and/or hinge regions of Pparγ1 are required for 
SIRT1 association and that both the K154/155A and the 
K154/155Q mutants have reduced SIRT1 binding ability.
Figure 3: Sirt1 and Pparγ are both required for maintaining essential metabolic pathways in the liver. (A) Schematic 
representation of microarray screening of deferentially expressed genes between Sirt1-/- mouse liver and Sirt1+/+ mouse liver. (B) Overlap 
of genes regulated by Pparγ overexpression and Sirt1 knockout in mouse liver. (C) KEGG pathways enriched for genes up-regulated 
in Pparγ overexpressing and Sirt1 knockout liver. (D). Gene Ontology Biological Processes enriched for genes up regulated in Pparγ 
overexpressing and Sirt1 knockout liver. Hypergeometric test used to identify deregulated ontologies associated with Pparγ overexpression 
and Sirt1 knockout. Fold induction ≥ 1.5 and P-value ≤ 0.05. 
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SIRT1 deletion and Pparγ gain-of-function govern 
common signaling pathways in vivo 
Given that Pparγ enhances adipogenesis [26] 
and Sirt1 attenuates adipogenesis [27], we investigated 
the possibility that SIRT1 deletion and Pparγ gain-of-
function may have common gene expression signatures 
in vivo.  Total RNA from liver samples was isolated from 
Sirt1-/- mice and littermate controls [28]. Microarray 
analysis identified 262 genes that were significantly 
down-regulated and 531 genes that were significantly 
increased in Sirt1-/- mouse liver relative to Sirt1+/+ mouse 
liver (P < 0.05, Fold > 1.5) (Fig. 3A, B and Table S1). 
Gene network analysis populated lipid metabolism as 
the major downstream target of Sirt1 (Tables S2). For 
the gene expression profile of Ppar gain-of-function, we 
took advantage of published data conducted in mouse 
liver injected with an adenovirus encoding mPparγ1 
[29]. The hepatic genes altered in Sirt1-/- mice were 
compared to those regulated by Pparγ1 overexpression. A 
significant number of genes (107 genes with 76 expected 
giving a fold enrichment of 1.4 and a P-value of 0.0001) 
were up-regulated by Pparγ1 overexpression and Sirt1 
gene deletion (Fig. 3B). Seven KEGG pathways and 23 
Biological Process Gene Ontologies were enriched for 
genes up-regulated by Pparγ1 overexpression and Sirt1 
gene deletion (Fig. 3C, D). Such pathways were mainly 
involved in lipid metabolism, including the biosynthesis 
of unsaturated fatty acids, fatty acid metabolism, and fatty 
acid oxidation. These data suggested SIRT1 and Pparγ 
converge to govern lipid metabolism in vivo.
The conserved acetylation sites of Pparγ 
determine lipid production
Given Sirt1 deacetylates Pparγ and inhibits 
adipogenesis, we reasoned that acetylation of Pparγ may 
promote lipid synthesis. In order to investigate the role 
of the conserved acetylation sites of Pparγ in lipogenesis, 
ErbB2 overexpressing breast cancer cells were used 
and lysyl residues were substituted with alanine (K to 
A) or glutamine (K to Q) to generate residues that were 
incapable of being acetylated. Substitution mutations 
(K154/155A, K154/155Q and K154/155R) of Pparγ1 
K154/155 were generated, and transduced into MCF10A-
NeuT cells. K77R of Pparγ1, a Pparγ mutant that is 
defective in SUMOylation [30, 31], was used as a 
positive control since this mutant induces adipogenesis 
in NIH3T3 cells. Following a differentiation protocol, 
Oil Red O staining followed by subsequent quantitative 
measurement was used to examine the lipid accumulation. 
Pparγ induced lipid accumulation which was further 
enhanced by Pparγ1 K77R (Fig. 4A). In contrast, the 
Pparγ1 K154/155A and the K154/155Q mutants were 
defective in the induction of adipogenic differentiation 
and lipid accumulation (Fig. 4A, B). Consistent with the 
ability of Pparγ to induce lipid formation, the relative 
protein abundance of the adipocyte Protein 2 (aP2) was 
induced by Pparγ1 and the Pparγ1 K77R mutant but 
not the K154/155A or K154/155Q mutants (Fig. 4C). 
Under differentiation conditions, the expression levels 
of the cell cycle regulators, cyclin D1 and cyclin E, 
were slightly increased or unchanged respectively (Fig. 
4C). Next, in order to study the gene expression profile 
regulated by Pparγ acetylation, microarray analysis was 
performed. Genome-wide expression analysis identified 
995 genes differentially expressed in Pparγ1-transduced 
MCF10A-NeuT cells (Tables S3). Among these, pathway 
analysis identified 127 genes populating the enhanced 
lipid metabolism pathway (Fig. 4D and Tables S4). Key 
enzymes required for de novo lipogenesis and β-oxidation 
are upregulated (highlighted by orange color) by wild-
type Pparγ, but not K154/155A or K154/155Q substitution 
mutants (Fig. 4E). Comparison of the gene expression 
pathways regulated by Pparγ vs. the K154/155Q (Fig. 4F) 
showed distinct pathways dependent upon the K154/155 
with the loss-of-function (Fig. 4F, I and Tables S5) or 
gain-of-function (Fig. 4F, III and Tables S6). Unchanged 
pathways are shown in Tables S7. These data suggest that 
substitution of lysyl residues with residues that cannot 
be acetylated (alanine (K to A) or glutamine (K to Q)) 
represents PPARγ acetylation-defective mutant in and 
that Pparγ acetylation at the conserved lysine motif serves 
as a molecular switch of Pparγ-mediated induction of 
lipogenesis in breast cancer cells. 
DISCUSSION
In this report, we have shown that the conserved 
acetylation site (K154/155) of Pparγ plays a critical role 
in breast cancer cell lipid synthesis. Firstly, we identified 
nine distinct acetylation sites in cultured cells by MS, and 
further confirmed the acetylation of K154/155 of Pparγ 
by in vivo labeling assay. We analyzed the function of 
K154/155 acetylation based on the conservation of this 
motif across species and evolutionally related nuclear 
receptors [14]. Our results showed that acetylation-
defective mutants of Pparγ are associated with 
decreased lipogenic differentiation in ErbB2-positive 
breast cancer cells, as shown by Oil Red O staining, 
protein expression of the classic adipocyte marker aP2, 
and mRNA expression of multiple lipogenic genes in 
microarray analysis. Decreased lipogenic function of 
the K154/155A and K154/155Q mutant was not due to 
changes of protein structure, cellular localization, and 
protein stability (unpublished data). This work provides 
a novel mechanism through which Pparγ regulates lipid 
metabolism via conserved acetylation sites in breast 
cancer cells. 
Acetylation is a dynamic post-translational 
modification of lysyl residues. Han et al. reported that 
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Figure 4: Acetylation-defective mutant of Pparγ is associated with decreased lipogenesis. (A) MCF10A-NeuT cells expressing 
various mutants of Pparγ were cultured until they were confluent, after 2 days, cells were stained with Oil Red O, and photographed. (B) 
Quantitative analysis of lipids in cells shown in (A) was performed by measuring the OD 520 nm of the Oil Red O stained cells eluted 
with 4% Igepal CA-40 in isopropanol (v/v). The results are shown as the average of three experiments; the bars indicate mean ± SEM. (C) 
Total cellular proteins from cells subjected to the same experimental protocol as in (A) were collected, and analyzed by Western blot as 
indicated. (D) Heat map of genes of lipid metabolism differentially regulated by Pparγ and vector control. (E) Schematic representation of 
the key enzymes of lipogenic signaling pathway. Genes upregulated by Pparγ are highlighted (orange color). (F) The genes differentially 
regulated in MCF10A-NeuT cells expressing wild-type Pparγ or Pparγ acetylation mutant were analyzed by the Ingenuity Pathway. The 
top five Canonical Pathways were listed corresponding to the loss of function with Pparγ acetylation mutant (I), the gain of function (III) 
and those unchanged by acetylation (II).
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acetylation and deacetylation of Pparγ is regulated by 
p300 and SIRT1 in the process of cell senescence [15], 
however no acetylated residues were identified. Recent 
publication by Li et al. mapped 5 acetylated lysyl residues 
(98, 107, 218, 268, and 293) in mouse Pparγ2 (68, 77, 
188, 238 and 263 in mPparγ1) by MS [16]. Among them, 
two evolutionally conserved residues in the helix 2-helix 
region, Lys268 and Lys293 were further investigated. 
These studies indicated that deacetylation of Pparγ at 
Lys268 and Lys293 by SIRT1 is required for maintaining 
the brown remodeling of white adipose tissue [16]. 
However, these prior studies did not analyze acetylation 
of the conserved lysine motif (K(R)xxKK) in Pparγ due to 
the limited coverage of the MS protocol used. Similar to 
the N-terminus of histone, the region “RIHKKSRNKC” 
is enriched with an overwhelming number of arginine and 
lysyl residues. Small fragments obtained by conventional 
trypsin digestion cannot be detected by conventional 
MALDI-TOF. Therefore, in our studies, trypsin mapping 
after a chemical-derivatization protocol was used to 
render lysine positions resistant to trypsin cleavage. This 
method increased the spectral counts and Mascot scores 
of acetylated peptides. A total of nine lysyl residues 
including K154 were identified. Among them, K188 and 
K238 in Pparγ1 correspond to K218 and K268 in Pparγ2, 
which were reported by Li et al [16]. Discrepancies in 
the identified Pparγ acetylation sites may be the results of 
two different experimental approaches and/or the choice 
of Pparγ isoform choose in these two studies. In our 
approach, we transfected HEK 293 cells with mPparγ1, 
and treated with TSA and NA, while in their report, HEK 
293 cells were co-transfected with expression vectors 
encoding mPparγ2 and acetyltransferase Cbp, followed 
by treatment with Rosiglitazone (a PPARγ agonist). 
Quantification of K154/155 acetylation was performed. 
The results suggest that the native acetylation levels of 
Pparγ are very low (1%), consistent with Li et al [16] in 
which the acetylation of mPparγ2 K268 and K293 was 
detected by MS only in the presence of Cbp. Acetylation 
of K155 was not detected by MS, most likely due to its 
inaccessibility by solvent as shown by a 3-dimensional 
structure analysis. Using an in vitro deacetylation assay, 
we demonstrated that a Pparγ peptide harboring acetylated 
K154 and K155 residues is a substrate for SIRT1 
deacetylation. Finally, in our in vivo labeling studies, the 
Pparγ mutant K154/155R conveyed significantly reduced 
incorporation of [3H] acetyl-CoA. Together, these results 
demonstrate that K154 and 155 are bona fide acetylation 
sites in vivo and are substrates for SIRT1 deacetylation. 
Han et al. reported the catalytic domain of SIRT1 
is necessary and sufficient for the interaction between 
Pparγ and SIRT1 and that the catalytically inactive 
SIRT1 mutant H363Y conveyed reduced association 
with Pparγ [15]. In our studies, the DBD and/or hinge 
regions of Pparγ were required for SIRT1 association. 
The K154/155A or K154/155Q mutants showed reduced 
association with SIRT1. These data are consistent with 
our MS data, where all nine acetylation lysyl residues 
identified by MS are located in the DNA binding domain 
and hinge domain of Pparγ. Our results indicate that 
SIRT1 binds and deacetylates Pparγ. This led us to 
investigate the pathways regulated by SIRT1 and Pparγ 
in vivo. As expected, a significant number of genes (107 
genes) were up-regulated by Pparγ overexpression and 
Sirt1 gene deletion. KEGG pathways and Biological 
Process Gene Ontologies populated lipid metabolism as 
the major term, including the biosynthesis of unsaturated 
fatty acids, fatty acid metabolism, and fatty acid oxidation. 
Recent studies have shown that the function of SIRT1 
in metabolic homeostasis requires NAD+-dependent 
deacetylase activity. Sterol regulatory element binding 
protein (SREBP) family proteins are critical regulators 
of lipogenesis and cholesterologenesis. Walker, et al. 
and Ponugoti, et al. showed that SIRT1 can directly 
deacetylate SREBPs, and that SIRT1 activity is important 
in the fasting-dependent attenuation of SREBP function 
[32, 33]. Several other nuclear receptors regulated by 
acetylation and deacetylation are also involved in lipid 
metabolism [34, 35]. Li, et al. reported that SIRT1 directly 
deacetylates LXRs, resulting in increased LXRs turnover 
and enhanced target gene expression [34]. LXRs are 
nuclear receptors that function as cholesterol sensors and 
regulate whole body cholesterol and lipid homeostasis. 
SIRT1 also regulates bile acid homeostasis through direct 
deacetylation of FXR. Down-regulation of hepatic SIRT1 
increases FXR acetylation with deleterious metabolic 
outcomes [35]. More recently, Li et al. showed that a 
gain-of-function SIRT1 promotes “browning” of WAT by 
deacetylating Pparγ at Lys268 and Lys293 [16]. Herein, 
we showed that loss-of-function of SIRT1 and gain-of-
function of Pparγ converge on liver lipid metabolism. The 
interaction between Pparγ and SIRT1 potentially controls 
the acetylation and deacetylation status of Pparγ protein. 
Therefore, deacetylation of Pparγ by SIRT1 could serve 
as a molecular switch that acts as key metabolic sensor. 
Enhanced lipogenesis is a hallmark of cancer 
cells [36]. This especially holds true in ErbB2-positive 
human breast cancer cells, which have a high degree of 
fat storage [37]. We have previously shown that active 
Pparγ promotes ErbB2-positive breast cancer growth 
through enhanced angiogenesis [21]. In the current study, 
we investigated the role of Pparγ K154/155 acetylation 
on lipid production in ErbB2-positive breast cancer 
cells. Adipogenic differentiation assays were performed 
to evaluate the function of these mutants in MCF10A 
cells transformed with oncogene NeuT. Consistent with 
data from Yamashita et al., Pparγ2 induced adipogenesis 
in NIH3T3 cells and a sumoylation-defective K107R 
mutant of Pparγ2 stimulates adipogenesis more robustly 
than the wild-type [31]. We showed that Pparγ induced 
lipid accumulation in MCF10A-NeuT cells, and the 
K77R mutant of Pparγ1 increased lipogenesis. Oil Red 
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O staining, lipogenic protein expression and genome-
wide expression analysis indicated that both K154/155A 
and K154/155Q mutants were defective in the induction 
of lipid accumulation and adipogenic differentiation. As 
shown in Figure 4, key enzymes and transcription factors 
required for de novo lipogenesis (SREBP, Insig and SCD) 
and β-oxidation (ACAA and MCD) are up-regulated 
by Pparγ wild-type, but not K154/155A or K154/155Q 
mutants. K154/155R mutant exhibited similar effect to 
Pparγ wild type (data not shown). In our prior publication, 
we showed that ERα acetylation governs ligand sensitivity, 
as all substitution mutants (K to A, Q and R) induced ERα 
hormone sensitivity [14]. Recently, Daniel et al. identified 
the progesterone receptor (PR) acetylation site within the 
conserved lysine motif KxKK (amino acids 638–641) 
[18]. Mutation of these three lysyl residues to alanine (A) 
or glutamine (Q) resulted in delayed phosphorylation, 
nuclear entry and transactivation of c-Myc, a known rapid 
response gene. In summary, SIRT1 deacetylates Pparγ at 
a conserved lysine motif. SIRT1 deletion and Pparγ gain-
of-function converge to govern lipid metabolism in vivo. 
We conclude that acetylation of Pparγ increases lipid 
synthesis. These data suggest that the Pparγ acetylation 
of the lysine motif serves as a molecular switch governing 
Pparγ-mediated induction of lipogenesis in ErbB2/
Her2 overexpressing breast cancer cells. It is of great 
importance to further investigate if lipogenesis regulated 
by acetylation of the Pparγ lysine motif (K154/155) 
contributes to the progression of ErbB2-positive breast 
cancer. 
MATERIALS AND METHODS
Cell culture, plasmid DNA, and transfection 
The HEK293, HEK293T cells were maintained in 
Dulbecco’s Modification of Eagle’s Medium (DMEM) 
supplemented with 10% fetal bovine serum, 1% penicillin, 
and 1% streptomycin. MCF10A-NeuT cells were cultured 
as previously described [38]. MCF10A-NeuT cells 
transduced with Pparγ1 or mutants were maintained in 
Dulbecco’s Modification of Eagle’s Medium (DMEM) 
supplemented with 10% fetal bovine serum, 1% penicillin, 
and 1% streptomycin. All cells were cultured in humidified 
atmosphere with 5% CO
2
 at 37°C. Rosiglitazone and 
15d-PGJ2 are from Cayman Chemical. 
The expression vectors encoding mouse Pparγ1 
are previously described [39]. The Pparγ1 point mutants 
were derived by site-directed mutagenesis using sequence-
specific primers. The wild-type and point mutants of 
Pparγ1 were individually cloned into p3xFLAG-CMV 
10 vector (Sigma) and MSCV-IRES-GFP vector. The 
internal deletion mutants of Pparγ1 were subcloned 
into p3xFLAG-CMV 10 vector using sequence-specific 
primers. The individual domain of Pparγ1 was digested by 
XbaI/BamHI from GAL4-DBD-HA-Pparγ1-AF1, DBD, 
Hinge and LBD (Gifts from Dr. Z. [40]), and then was 
subcloned into p3xFLAG-CMV 10 vector. The integrity 
of all constructs was confirmed by sequence analysis. 
The Myc-tagged wild-type and mutant (H363Y) SIRT1 
expression constructs in pcDNA3.1 were previously 
described [41]. 
Cell transfection and infection were performed 
as previously described [42, 43]. Retroviruses were 
prepared by transient cotransfection of vector expressing 
Pparγ1, mutants or empty vector together with the helper 
viral vector into 293T cells using calcium phosphate 
precipitation. The retroviral supernatants were harvested 
48 h after transfection and filtered through a 0.45 µm 
filter. Mammary epithelial cells MCF10A-NeuT cells 
were incubated with fresh retroviral supernatants in the 
presence of 8 µg/ml polybrene for 24 hrs, cultured for a 
further 48 hrs, and subjected to different assays.
In vivo [3H]-acetyl-CoA labeling. 
Labeling of Pparγ was conducted using the 
previously described protocol with some modifications 
[44]. Briefly, one 10-cm plate of 293 cells was used for in 
vivo acetyl group labeling. The cells transfected either with 
expression vector or control were maintained in DMEM 
w/ 10% FBS at over 80% confluence. The cells were first 
were treated with 1µM TSA and 10 mM NA for 4 hours, 
and then transferred to DMEM medium containing 1µM 
TSA, 10 µM NA and 1 mCi/ml [3H]-sodium acetate (75–
150 mCi/mmol) (Perkin Elmer) for 1hr. Cells were washed 
twice with ice-cold PBS and lysed in RIPA buffer with 
freshly added protease inhibitor cocktail supplemented 
with fresh DTT (1 mM) and PMSF (1 mM). The lysates 
were centrifuged at 14,000 rpm for 15 min at 4°C. 
Supernatants were incubated with antibody conjugated 
to agarose beads, for 6 to 12 hrs at 4°C. Immunopurified 
proteins were resolved on SDS–PAGE gels. Gels were 
either staining with Coomassie blue and then dried, or 
directly dried and subjected to autoradiography at -70°C 
for 2-4 weeks.
Identification of Pparγ acetylated lysine residue 
using MS
Preparation and proteolytic digestion of 
Pparγ: 3xFLAG-tagged Pparγ1 was purified by 
immunoprecipitation, using anti-FLAG M2 affinity gel, 
and the bound material was eluted using a soft SDS-
elution protocol in order to selectively elute the bound 
recombinant protein and not the anti-FLAG antibody. 
This eluent was concentrated on a speedvac and further 
separated on SDS-PAGE and stained with Coomassie 
blue. The major band at 55 kDa was cut. The gel pieces 
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were completely dehydrated and subsequently reduced 
and alkylated. To improve coverage of the basic regions 
of Pparγ1 sequences, the gel isolated protein was mapped 
using a modified trypsin mapping protocol as below. 
Chemical modification of lysine and tryptic mapping 
of acetylation site: Chemical modification was achieved 
after the reduction/alkylation steps. In detail, the gel was 
hydrated with 10 µl of deuterated acetic anhydride, 20 
µl of 100 mM ABC (pH 8), and mixing. The acetylation 
reaction is fast and results in acidification of the solution, 
so 70 µl of 100 mM ABC is immediately added and the 
solution is incubated at 37°C for 5 minutes. The pH is 
measured within the first 5 minutes and adjusted to 7-8. 
After an additional 30 minute incubation at 37°C, the 
supernatant is removed and the gel pieces are washed 
twice with water, and then dehydrated by successive 
washes (with vortexing, as above) in 100 µl of 50 mM 
ABC, then 100 µl 50 mM ABC with 50% acetonitrile (50-
ACN), and finally 100% ACN. This chemical treatment 
derivatized lysyl residues with a deuterated acetyl group 
(a 45Dalton mass increase) and rendered lysine positions 
resistant to trypsin cleavage. Deuterated acetic anhydride 
was used to allow differentiation from the native acetyl 
group (a 42 Dalton modification group).
Trypsin (200 ng in 50 µl of 50 mM ABC) is then 
added to hydrate the gel slices. After an hour at room 
temperature, additional 50 mM ABC and 10% ACN was 
added to ensure that the gel pieces were always covered 
with solvent. The digest was transferred to 37°C and 
digested overnight. Next, the supernatant was transferred 
to LoBind tubes (Eppendorf) and the remaining peptides 
were extracted by adding sufficient 50% ACN, 5% 
Trifluoroacetic acid to cover the gels and by vortexing 
for 25 minutes. This step was repeated and each of the 
three supernatants were combined and lyophilized in a 
Speedvac. 
Mass spectrometry analysis: Dehydrated peptides 
were resuspended in 5% acetonitrile, 0.05% formic acid 
and immediately loaded on a nano-spray tip for LC-MS/
MS analysis. 10 - 15% of the peptide digest is loaded on 
a Magic C18 AQ (Michrom) nanospray tip, packed to 
5 cm. This tip was loaded, using a pressure bomb, and 
washed, after installation on the HPLC of a Thermo 
LTQ mass spectrometer, with 5% methanol, 0.1% formic 
acid, for 10 min with a flow rate of 600 nl/minute (about 
10 column volumes = 6.6 µl) The peptide digests were 
analyzed in an LC-MS/MS run, using a 5-15 % methanol 
gradient over 2.5 minutes, followed by a 15-60% methanol 
gradient for 67 minutes, a 60% methanol isocratic step of 
4 minutes, ending with a 3-minute 95% methanol step, 
with all solvents containing 0.1% formic acid. A full MS 
survey scan is performed every 3 seconds and the top 7 
peaks are selected to produce MS/MS fragmentation 
spectrum. In order to confirm if K154/155 is acetylated, 
the same peptide digest was run a second time, under 
identical HPLC conditions. With the mass spectrometer 
programmed with an inclusion filter of 383-431 m/z to 
select for doubly charged peptides in the size range of 
the IHKKSR hexa-peptide in its unmodified and fully 
derivatized states. This selective method allows for the 
determination of the relative frequency of the modified 
and unmodified IHKKSR peptides, by evaluating the 
spectral count ratios. 
Mapping of proteolytic peptide fragments and 
acetylation sites: The MS and MS/MS fragmentation 
spectrum data were used in a Mascot search of the whole 
mouse proteome. To identify peptide sequences modified 
with acetyl groups, a custom database, containing 
the recombinant Pparγ sequence, was also searched. 
The following search criteria were used for selecting 
fragmentation spectra that map to proteolytic peptides: 
peptide tolerance = -0.8 to +0.5, a minimum ion score of 
15, and a fragmentation spectrum, containing fragment 
ions that either include or flank the acetylated amino 
acid position. Mascot searches were conducted, allowing 
for multiple positive charge-states, 2, 3, or 4 missed 
cleavage sites, fixed S-carboxyamidomethyl modification 
of cysteine and variable methionine oxidation and lysine 
acetylation. Mascot searches use trypsin digestion, but 
allow for 4 or 5 missed trypsin cleavages, and variable 
deuterated acetyl (45 Da) and native acetyl (42 Da) 
modification. 
Determination of the deacetylation site in Pparγ 
peptide in vitro
To determine the Michaelis-Menten curves of 
SIRT1-catalyzed deacetylation of Pparγ and p53, the Pparγ 
peptide CDLNCRIHXXSRNKCQY and the p53 peptide 
GSRAHSSHLXSXXGQSTSRHRXLMFXTEGPDSD 
where “X” is AcK (Rockefeller Proteomics Resource) . 
The enzymatic reaction was initiated by adding SIRT1 
into the solution containing the peptide. For the Pparγ 
peptide, the Pparγ peptide of different concentrations was 
incubated with 4 μM SIRT1, 500 μM NAD, and 500 μM 




 buffer of pH 8. The reaction 
was quenched with 10% TFA after 10 minutes incubation 
at 37oC. The Pparγ peptide and the deacetylated peptide 
were separated by HPLC (Hitachi LaChrom Elite HPLC 
system) using a C18 5 µm column (Waters) with gradient 
acetonitrile and 0.1%TFA as eluent. The areas of peaks 
for peptides were used for quantification. For the p53 
peptide, the p53 peptide of different concentrations was 





 buffer of pH 8 at 37oC. The enzymatic product 
acetyl adenosine diphosphate ribose (AADPR) was 
monitored by HPLC using C18 column (Waters) with 20 
mM NH
4
OAc as eluent. The area of AADPR peak was 
used for quantification. The turnover rate versus the Pparγ 
peptide and p53 peptide concentration was fitted with 
Kaleida Graph software, and Km and kcat were determined.
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In order to determine the deacetylation site in the 
Pparγ peptide, 200 μM Pparγ was incubated with 4 μM 
SirT1 for 20 minutes in the reaction of 1.25 mL. The 
deacetylated peptide was separated from the Pparγ peptide 
by HPLC as previously described and collected. The 
lyophilized product was analyzed for mass spectrometry 
at the Proteomics Resource Center in the Rockefeller 
University. In the analysis, the samples of Pparγ and 
the deacetylated Pparγ were separately mixed with 50% 
aqueous methanol solution (vol:vol=1:1) and loaded 
into a glass nanospray PicoTip (New Objectives). The 
samples were analyzed by nano-electrospray tandem mass 
spectrometry with an ABI QSTAR mass spectrometer.
Immunoprecipitation and Western blot
HEK293T or HEK293 cells were transfected with 
an expression vector as indicated in the figure. 24 h after 
transfection, the cells were harvested in cell lysis buffer 
(50 mM HEPES (pH 7.2), 150 mM NaCl, 1 mM EDTA, 1 
mM EGTA, 1 mM DTT, 0.1% TritonX-100) supplemented 
with protease inhibitor mixture (Roche Diagnostics). 
Whole cell lysates (500 µg) were immunoprecipitated with 
10µl of M2 beads (A2220; Sigma) or 2 µg of antibodies as 
indicated. Immunoprecipitates were washed 5 times with 
cell lysis buffer and resolved by SDS-PAGE gel followed 
by Western blot with the indicated antibodies. Antibodies 
used were: anti- FLAG® M2 Affinity Gel (M2; Sigma), 
anti- PPARγ (H100 and E8), anti-SIRT1 (H-300), anti-
cyclin E (M-20), anti-aP2 (C-15), anti-β-actin (C4) (Santa 
Cruz), and anti-cyclin D1 (DCS-6; Santa Cruz or Ab3; 
NeoMarker). The abundance of immunoreactive protein 
was quantified using a densitometer (Image Quant version 
1.11, Molecular Dynamics Computing Densitometer, 
Sunnyvale, CA). 
Adipogenic differentiation and Oil Red O staining
MCF10A-NeuT cells expressing various mutants 
of Pparγ1 were maintained at confluence for 2 days and 
treated with vehicle control or ligand for 2 days. Oil Red O 
staining of cells has been previously described [43]. 
Microarray analysis
Total RNA was isolated from MCF10A-NeuT cells 
transduced with Pparγ1 or acetylation defective mutant 
after adipogenic differentiation protocol. RNA quality 
was determined by an Agilent 2100 bioanalyzer. Probe 
synthesis and hybridization to Affymetrix gene chips, 
human gene 1.0 ST array (Affymetrix, Santa Clara, CA) 
were performed according to the manufacturer’s manual. 
Chips were scanned on an Affymetrix Gene Chip Scanner 
3000, using Command Console Software. Background 
correction and normalization were done using Iterative 
plier 16 with GeneSpring V12.0 software (Agilent, Palo 
Alto, CA, USA). 1.5-fold (p value <0.05) differentially 
expressed gene list was generated. The differentially 
expressed gene list was loaded into Ingenuity Pathway 
Analyses (IPA) 8.0 software (http://www.ingenuity.com) 
to perform biological network and functional analysis. 
Expression profiles are displayed using Treeview. 
Microarray analysis was also performed with total RNA 
samples from Sirt1+/+ and Sirt1-/- mice liver [28]. Pathway 
analysis was performed using and Kyoto Encyclopedia 
of Genes and Genomes (KEGG). Gene Ontology (GO) 
analysis was performed for gene functions. 
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